Assessment of drug-related migraine in a real-world large-scale database

Assessment of drug-related migraine in a real-world large-scale database

BackgroundDrug-induced migraine represents a clinically significant yet under-investigated subtype of migraine. This study aims to evaluate the risk of drug-related migraine based on real-world data from the FDA Adverse Event Reporting System (FAERS).MethodsA retrospective pharmacovigilance analysis...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fan Wu, Ao Liu, Zhenyuan Jiang, Zhonglin Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Pharmacology
Subjects:	migraine drug-induced headache FAERS pharmacovigilance disproportionality analysis BCPNN
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1647088/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Pan Ding, et al.
Published: (2025-03-01)

A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System
by: Dongdong Zhang, et al.
Published: (2024-12-01)

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
by: Ye Hu, et al.
Published: (2025-02-01)

Conducting a real-world study of Tumor Necrosis factor-alpha inhibitors-induced Systemic Lupus Erythematosus based on the FAERS database
by: Mengjiao He, et al.
Published: (2025-02-01)

Real world pharmacovigilance assessment of drug related macular degeneration risks
by: Xiaodong Chen, et al.
Published: (2025-01-01)

Sex-specific risk signals and onset patterns of drug-induced peripheral neuralgia: a 20-year pharmacovigilance analysis based on FAERS real-world dat
by: Xianyan Wang, et al.
Published: (2025-08-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database
by: Lu Liu, et al.
Published: (2025-07-01)

Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin
by: Zhi Wang, et al.
Published: (2025-05-01)

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database
by: Fang Wu, et al.
Published: (2025-02-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
by: Junchen Chen, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis
by: Chen J, et al.
Published: (2025-06-01)

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system
by: Yu Zhang, et al.
Published: (2024-12-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
by: Nan Chen, et al.
Published: (2025-06-01)

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
by: Wensheng Liu, et al.
Published: (2025-05-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
by: Meng Liu, et al.
Published: (2025-08-01)

Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis
by: Junli Dong, et al.
Published: (2025-08-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
by: Bingqing Wang, et al.
Published: (2025-05-01)

Real world pharmacovigilance study of antineoplastic drug related vitiligo risks
by: Yixuan Yang, et al.
Published: (2025-07-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Real-world assessment of thromboembolic risk associated with tamoxifen
by: Jiajia Jia, et al.
Published: (2025-07-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database
by: Tongtong Wang, et al.
Published: (2025-04-01)

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Zhiyuan Zhang, et al.
Published: (2024-11-01)

Adverse events reporting of edaravone: a real-world analysis from FAERS database
by: Qi Shang, et al.
Published: (2025-03-01)

Real-world assessment of sparsentan’s drug safety framework
by: Wenjing Fu, et al.
Published: (2025-12-01)